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Abstract: Well-differentiated papillary mesothelioma is a patho-
logic entity distinct from malignant mesothelioma and has a differ-
ent tumor biology highlighted by its relatively good prognosis. We
report the case of a 27-year-old woman with pleural well-differen-
tiated papillary mesothelioma, who was treated with bilateral pleu-
rodesis and pericardial window to control the production of malig-
nant fluid, without significant systemic anticancer treatment. She
survived for 16 years, confirming its indolent nature. This case
report also highlights the role of fluid cytology, immunohistochem-
istry, and electron microscopy in the diagnosis of well-differentiated
papillary mesothelioma and the potential use of serum CA-125 as a
marker of progression.
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(J Thorac Oncol. 2009;4: 920–922)
CASE REPORT
A 27-year-old woman who was a nonsmoker with no
known asbestos exposure presented with dyspnea and cough
in May 1992. On clinical examination and imaging, she had
a right pleural effusion. She underwent right pleural decorti-
cation and talc pleurodesis. Intraoperatively, a right pleural
tumor encasing the hemithorax was identified. Pathology was
reported to show fibroadipose tissue infiltrated by mucin-
secreting moderately differentiated adenocarcinoma of pre-
dominantly acinar or cribriform pattern, but papilliform areas
were also present. It showed positive staining for broad-
spectrum cytokeratin (Cam 5-2 and AE1/AE3), epithelial
membrane antigen, human epithelial antigen, and CA-125.
The computed tomography scan of her abdomen and pelvis
showed no evidence of ovarian cancer or primary peritoneal
carcinomatosis. She was started on tamoxifen 40 mg daily as
a breast primary would potentially be most responsive.
She remained on tamoxifen for 2 years with stable
radiologic disease of her right pleura. She remained well until
May 1999 when she developed a pericardial effusion and a
pericardiocentesis was performed.
Pericardial fluid cytology yielded clusters of regular
tumor cells of mesothelial appearance. Immunohistochemical
stains on cell block sections showed scattered positive stain-
ing for the mesothelial marker calretinin, in addition to the
above positive stains. The cells contained abundant glycogen,
but no epithelial mucin was identified. Electron microscopy
was also performed. It revealed cells that contained long
microvilli on the free surfaces, prominent clumped tonofila-
ments in the cytoplasm, and well-formed intercellular junc-
tions, supporting a mesothelial origin of the cells. The overall
findings were consistent with well-differentiated papillary
mesothelioma (WDPM). On review of the original pathology,
the diagnosis was then revised (Figure 1).
She started on imatinib mesylate (STI571, Glivec) as
part of a clinical trial1 in February 2002 and continued the
same for 4 months. She did not derive any clinical benefit but
did experience significant anemia and increased pain.
She had recurrence of pericardial effusion resulting in
cardiac tamponade in August 2003. Left thoracotomy and
pericardial window were performed. The biopsy of the peri-
cardium was consistent with WDPM.
She had left pleurodesis in November 2006 because of
recurrent left pleural effusion suggestive of progressive dis-
ease. She declined any specific systemic anticancer treatment
but continued on supportive measures.
Her serum CA-125 gradually increased from 97 U/ml
in July 1999 to 983 U/ml in March 2008 (Figure 2). In April
2008, she presented with increasing ascites. This was thera-
peutically drained and cytology was again consistent with
WDPM. Her disease gradually progressed and she died of
progressively worsening respiratory failure in May 2008.
DISCUSSION
Well-differentiated papillary mesothelioma is well de-
scribed in the literature, with most reported cases arising from
the peritoneum in women of reproductive age. There have
been two small case series of WDPM of the pleura,2,3 along
with two other case reports,4,5 with a total of 17 men and 16
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women, reported in the English-language papers. This case
report describes the youngest patient to have pleural WDPM.
WDPM displays a characteristic histologic pattern with
diffuse formation of papillae lined by relatively bland me-
sothelial cells, often with subnuclear vacuolation and absence
of mitoses. Invasion of the submesothelial layer is absent or
minimal. Unlike malignant mesothelioma, WDPM have gen-
erally lacked an association with asbestos exposure, particu-
larly in the peritoneum.
In 11 patients with a minimal follow-up period of 24
months in the Galateau-Salle et al.3 series, the survival ranged
from 36 to 180 months, with an average of 74 months. This
case report certainly confirms the indolent natural history of
WDPM with a long survival of 16 years from the time of
diagnosis.
Cytologic examination of fluids with immunohisto-
chemical stains on cell block sections and electron micros-
copy are effective in establishing the diagnosis of WDPM and
in confirming recurrences. Numerous clusters or “collagen
balls” have been described in a recent report.6
The optimal management including the role of chemo-
therapy in the treatment of pleural WDPM remains unknown.
There is no clear pattern as to whether specific treatment such
as surgery, radiotherapy, or chemotherapy altered the natural
history of this disease.2,3 In the series reported by Daya and
McCaughey,7 it was suggested that chemotherapy had an
adverse outcome. In contrast, Baratti et al.8 reported that
definitive tumor eradication of peritoneal disease by means of
cytoreduction and hyperthermic intraperitoneal chemother-
apy seems to be effective in preventing disease recurrence
and transition to an aggressive malignancy. However, this
case report demonstrated the importance of surgical proce-
dures such as pleurodesis and pericardial window in the
management of fluid production in the treatment of this
condition.
The cancer antigen CA-125 is a high-molecular mass
glycoprotein produced by cells of ovarian cancer and normal
cells derived from coelomic epithelium. Neither the serum
CA-125 nor the immunohistochemical staining of CA-125 in
cells is specific, but is most strongly associated with epithelial
FIGURE 1. A, Fluid with clusters of tumor cells (PAP stain). B, Cell block of fluid showing scattered calretinin-positive cells. C,
Electron microscopy showing long microvilli (arrows).
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gynecologic tumors such as the ovarian carcinoma. Other
cells of origin that may react positive for CA-125 immuno-
histochemistry include the lung and breast but also the epi-
thelial cells of the conjunctiva and prostate glandular epithe-
lium. The elevation of serum CA-125 may occur in other
malignant conditions such as lung, bladder, gastric, hepatic and
pancreatic cancers, leukemia, non-Hodgkin lymphoma, and me-
diastinal teratoma; benign conditions such as cardiac failure,
pleuropulmonary diseases, chronic liver disease, connective tis-
sue disease, peritoneal dialysis, and recent surgery; and up to 2%
of normal healthy individuals. There is recent evidence that 85%
of diffuse malignant epithelioid mesothelioma stains for CA-
125.9 Furthermore, the serum CA-125 is elevated in most pa-
tients with peritoneal mesothelioma in one series and the serial
measurements paralleled treatment response and relapse, sug-
gesting a potential role of serum CA-125 in the disease moni-
toring of malignant mesothelioma.10
Interestingly, this woman’s serum CA-125 seems to have
gradually increased over the years accelerating toward the end of
her life. This may indicate that CA-125 could be a marker of
WDPM progression. However, it may simply reflect other fac-
tors such as gradual accumulation of pleural effusion and ascites.
To our knowledge, neither CA-125 immunohistochemical stain-
ing for WDPM nor the use of serum CA-125 as a marker of
WDPM has been reported in the English literature.
This case report adds the youngest patient so far to the
small body of literature on pleural WDPM, confirming the
indolent time course of this disease without significant sys-
temic anticancer treatment, but the importance of the surgical
procedures to manage malignant pleural and pericardial fluid
is demonstrated. It also demonstrates that the involvement of
other mesothelial surfaces, such as pericardium and perito-
neum, occurs with this tumor. Fluid cytology, immunohisto-
chemistry, and electron microscopy were useful in making
the diagnosis of recurrent WDPM. The potential usefulness
of serum CA-125 as a marker for WDPM is emphasized.
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FIGURE 2. The increase of CA-125 over time.
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